The expression of PRF1 has been used to assess tumor-infiltrating lymphocytes in the tumor microenvironment and was related to the response of patients treated with anti-CTLA-4 therapy and anti-PD-1/PD-L1 therapy [37, 38]. The gene discussed is CTLA4; the disease is neoplasm.